Advanced Gene Delivery
What is it?
AqGene™ is our supramolecular solution for health care, developing novel approaches to delivering medicines to patients.
AqGene™ provides safe and efficacious gene delivery technology, using unique non-viral supramolecular polymer particles to unlock the potential of gene therapies for improving patient lives. We work closely with partners in the healthcare industry, developing novel and tailored approaches to delivering medicines to patients.
Why is it needed?
The promise of DNA and RNA-vaccines and therapeutics has yet to be realised for the lack of safe, efficacious, and specific delivery vectors. Viral vectors are naturally equipped to evoke maximal gene expression but are known to generate immune responses in clinical trials.
In contrast, cationic polymers and lipids demonstrate superior safety but do not afford clinically relevant levels of gene expression. The efficiency of non-viral vectors is reportedly 1/10th to 1/1000th that reported for viral vectors.
Why is it unique?
AqGene™ makes products more compatible for applications with formulation flexibility and improved active stability, thereby providing targeted delivery of actives on demand. In gene therapy, our non-viral vehicles have the potential to approach the performance of natural systems while less likely to trigger immunogenic responses. Our modular approach to delivery means greater flexibility to overcome significant challenges of stabilisation and delivery.
What are its other benefits?
• Safe and efficacious non-viral supramolecular gene delivery developed with Cambridge University
• Less likely to trigger immune responses like viral vectors do
• Targeted delivery of actives due to improved stability
What are its applications?
We are continually discovering exciting new healthcare applications for this breakthrough gene delivery technology for:
• Transient transfection
• Therapeutic gene delivery
• Protein encapsulation
• Small molecule release
What is the opportunity for our partners?
AqGene™, a proprietary technology, offers our partners the potential to allow new product development and patent life extension with existing actives.